Using metabolomics to assess myocardial metabolism and energetics in heart failure

Journal of Molecular and Cellular Cardiology

Volumn 55, Issue 1, 2013, Pages 12-18

  Turer, Aslan T ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Congestive heart failure; Energetics; Metabolomics

Indexed keywords

AMINO ACID; KETONE BODY; PENTOSE PHOSPHATE;

BIOCHEMISTRY; BIOENERGY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL DAMAGE; CELL METABOLISM; CITRIC ACID CYCLE; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ENERGY RESOURCE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE METABOLISM; HUMAN; ISCHEMIC HEART DISEASE; LIPOTOXICITY; METABOLIC DISORDER; METABOLOMICS; NONHUMAN; OXIDATION; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ENERGY METABOLISM; HEART FAILURE; HUMANS; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; MYOCARDIUM; OXIDATION-REDUCTION;

ANIMALIA;

EID: 84872677864     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.08.025     Document Type: Review

References (87)

1. Heidenreich P.A., Trogdon J.G., Khavjou O.A., Butler J., Dracup K., Ezekowitz M.D., et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation Mar 1 2011, 123(8):933-944.
2. Roger V.L., Weston S.A., Redfield M.M., Hellermann-Homan J.P., Killian J., Yawn B.P., et al. Trends in heart failure incidence and survival in a community-based population. JAMA Jul 21 2004, 292(3):344-350.
3. Dunlay S.M., Redfield M.M., Weston S.A., Therneau T.M., Hall Long K., Shah N.D., et al. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol Oct 27 2009, 54(18):1695-1702.
4. Levy D., Kenchaiah S., Larson M.G., Benjamin E.J., Kupka M.J., Ho K.K., et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med Oct 31 2002, 347(18):1397-1402.
5. Beer M., Seyfarth T., Sandstede J., Landschutz W., Lipke C., Kostler H., et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol Oct 2 2002, 40(7):1267-1274.
6. Starling R.C., Hammer D.F., Altschuld R.A. Human myocardial ATP content and in vivo contractile function. Mol Cell Biochem Mar 1998, 180(1-2):171-177.
7. Wallimann T. Bioenergetics. Dissecting the role of creatine kinase. Curr Biol Jan 1 1994, 4(1):42-46.
8. Meyer R.A., Sweeney H.L., Kushmerick M.J. A simple analysis of the "phosphocreatine shuttle". Am J Physiol May 1984, 246(5 Pt 1):C365-C377.
9. Bristow M.R., Anderson F.L., Port J.D., Skerl L., Hershberger R.E., Larrabee P., et al. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation Sep 1991, 84(3):1024-1039.
10. Nascimben L., Ingwall J.S., Pauletto P., Friedrich J., Gwathmey J.K., Saks V., et al. Creatine kinase system in failing and nonfailing human myocardium. Circulation Oct 15 1996, 94(8):1894-1901.
11. Sylven C., Lin L., Jansson E., Sotonyi P., Fu L.X., Waagstein F., et al. Ventricular adenine nucleotide translocator mRNA is upregulated in dilated cardiomyopathy. Cardiovasc Res Jul 1993, 27(7):1295-1299.
12. Ingwall J.S. Transgenesis and cardiac energetics: new insights into cardiac metabolism. J Mol Cell Cardiol Sep 2004, 37(3):613-623.
13. Kaasik A., Veksler V., Boehm E., Novotova M., Minajeva A., Ventura-Clapier R. Energetic crosstalk between organelles: architectural integration of energy production and utilization. Circ Res Jul 20 2001, 89(2):153-159.
14. Boehm E., Ventura-Clapier R., Mateo P., Lechene P., Veksler V. Glycolysis supports calcium uptake by the sarcoplasmic reticulum in skinned ventricular fibres of mice deficient in mitochondrial and cytosolic creatine kinase. J Mol Cell Cardiol Jun 2000, 32(6):891-902.
15. Ten Hove M., Chan S., Lygate C., Monfared M., Boehm E., Hulbert K., et al. Mechanisms of creatine depletion in chronically failing rat heart. J Mol Cell Cardiol Feb 2005, 38(2):309-313.
16. Boehm E., Chan S., Monfared M., Wallimann T., Clarke K., Neubauer S. Creatine transporter activity and content in the rat heart supplemented by and depleted of creatine. Am J Physiol Endocrinol Metab Feb 2003, 284(2):E399-E406.
17. Li H., Thali R.F., Smolak C., Gong F., Alzamora R., Wallimann T., et al. Regulation of the creatine transporter by AMP-activated protein kinase in kidney epithelial cells. Am J Physiol Renal Physiol Jul 2010, 299(1):F167-F177.
18. Wallis J., Lygate C.A., Fischer A., ten Hove M., Schneider J.E., Sebag-Montefiore L., et al. Supranormal myocardial creatine and phosphocreatine concentrations lead to cardiac hypertrophy and heart failure: insights from creatine transporter-overexpressing transgenic mice. Circulation Nov 15 2005, 112(20):3131-3139.
19. Saupe K.W., Spindler M., Tian R., Ingwall J.S. Impaired cardiac energetics in mice lacking muscle-specific isoenzymes of creatine kinase. Circ Res May 4 1998, 82(8):898-907.
20. Gupta A., Akki A., Wang Y., Leppo M.K., Chacko V.P., Foster D.B., et al. Creatine kinase-mediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved. J Clin Invest Jan 3 2012, 122(1):291-302.
21. Yamashita H., Bharadwaj K.G., Ikeda S., Park T.S., Goldberg I.J. Cardiac metabolic compensation to hypertension requires lipoprotein lipase. Am J Physiol Endocrinol Metab Sep 2008, 295(3):E705-E713.
22. Augustus A.S., Buchanan J., Park T.S., Hirata K., Noh H.L., Sun J., et al. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem Mar 31 2006, 281(13):8716-8723.
23. Zhou Y.T., Grayburn P., Karim A., Shimabukuro M., Higa M., Baetens D., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A Feb 15 2000, 97(4):1784-1789.
24. Glenn D.J., Wang F., Nishimoto M., Cruz M.C., Uchida Y., Holleran W.M., et al. A murine model of isolated cardiac steatosis leads to cardiomyopathy. Hypertension Feb 2011, 57(2):216-222.
25. Park T.S., Hu Y., Noh H.L., Drosatos K., Okajima K., Buchanan J., et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res Oct 2008, 49(10):2101-2112.
26. Sharma S., Adrogue J.V., Golfman L., Uray I., Lemm J., Youker K., et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J Nov 2004, 18(14):1692-1700.
27. Boudina S., Abel E.D. Diabetic cardiomyopathy revisited. Circulation Jun 26 2007, 115(25):3213-3223.
28. Mathur A., Sims H.F., Gopalakrishnan D., Gibson B., Rinaldo P., Vockley J., et al. Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. Circulation Mar 16 1999, 99(10):1337-1343.
29. Saudubray J.M., Martin D., de Lonlay P., Touati G., Poggi-Travert F., Bonnet D., et al. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis Jun 1999, 22(4):488-502.
30. Longo N., Amat di San Filippo C., Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet May 15 2006, 142C(2):77-85.
31. Osorio J.C., Stanley W.C., Linke A., Castellari M., Diep Q.N., Panchal A.R., et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation Jul 30 2002, 106(5):606-612.
32. Recchia F.A., Osorio J.C., Chandler M.P., Xu X., Panchal A.R., Lopaschuk G.D., et al. Reduced synthesis of NO causes marked alterations in myocardial substrate metabolism in conscious dogs. Am J Physiol Endocrinol Metab Jan 2002, 282(1):E197-E206.
33. Sack M.N., Rader T.A., Park S., Bastin J., McCune S.A., Kelly D.P. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation Dec 1 1996, 94(11):2837-2842.
34. Razeghi P., Young M.E., Alcorn J.L., Moravec C.S., Frazier O.H., Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation Dec 11 2001, 104(24):2923-2931.
35. Ide T., Tsutsui H., Hayashidani S., Kang D., Suematsu N., Nakamura K., et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res Mar 16 2001, 88(5):529-535.
36. Ide T., Tsutsui H., Kinugawa S., Utsumi H., Kang D., Hattori N., et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res Aug 20 1999, 85(4):357-363.
37. Scheubel R.J., Tostlebe M., Simm A., Rohrbach S., Prondzinsky R., Gellerich F.N., et al. Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression. J Am Coll Cardiol Dec 18 2002, 40(12):2174-2181.
38. van Bilsen M., van Nieuwenhoven F.A., van der Vusse G.J. Metabolic remodelling of the failing heart: beneficial or detrimental?. Cardiovasc Res Feb 15 2009, 81(3):420-428.
39. Rajabi M., Kassiotis C., Razeghi P., Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev Dec 2007, 12(3-4):331-343.
40. Turer A.T., Malloy C.R., Newgard C.B., Podgoreanu M.V. Energetics and metabolism in the failing heart: important but poorly understood. Curr Opin Clin Nutr Metab Care Jul 2010, 13(4):458-465.
41. Davila-Roman V.G., Vedala G., Herrero P., de las Fuentes L., Rogers J.G., Kelly D.P., et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol Jul 17 2002, 40(2):271-277.
42. Neglia D., De Caterina A., Marraccini P., Natali A., Ciardetti M., Vecoli C., et al. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol Dec 2007, 293(6):H3270-H3278.
43. Paolisso G., Gambardella A., Galzerano D., D'Amore A., Rubino P., Verza M., et al. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism Feb 1994, 43(2):174-179.
44. Wallhaus T.R., Taylor M., DeGrado T.R., Russell D.C., Stanko P., Nickles R.J., et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation May 22 2001, 103(20):2441-2446.
45. Taylor M., Wallhaus T.R., Degrado T.R., Russell D.C., Stanko P., Nickles R.J., et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in Patients with Congestive Heart Failure. J Nucl Med Jan 2001, 42(1):55-62.
46. Stolen K.Q., Kemppainen J., Kalliokoski K.K., Hallsten K., Luotolahti M., Karanko H., et al. Myocardial perfusion reserve and oxidative metabolism contribute to exercise capacity in patients with dilated cardiomyopathy. J Card Fail Apr 2004, 10(2):132-140.
47. Funada J., Betts T.R., Hodson L., Humphreys S.M., Timperley J., Frayn K.N., et al. Substrate utilization by the failing human heart by direct quantification using arterio-venous blood sampling. PLoS One 2009, 4(10):e7533.
48. Turer A.T., Stevens R.D., Bain J.R., Muehlbauer M.J., van der Westhuizen J., Mathew J.P., et al. Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation Apr 7 2009, 119(13):1736-1746.
49. Griffin J.L., Atherton H., Shockcor J., Atzori L. Metabolomics as a tool for cardiac research. Nat Rev Cardiol Nov 2011, 8(11):630-643.
50. Wishart D.S., Knox C., Guo A.C., Eisner R., Young N., Gautam B., et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res Jan 2009, 37:D603-D610. [Database issue].
51. Rhee E.P., Gerszten R.E. Metabolomics and cardiovascular biomarker discovery. Clin Chem Jan 2012, 58(1):139-147.
52. Kato T., Niizuma S., Inuzuka Y., Kawashima T., Okuda J., Tamaki Y., et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail May 2010, 3(3):420-430.
53. Pound K.M., Sorokina N., Ballal K., Berkich D.A., Fasano M., Lanoue K.F., et al. Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy. Circ Res Mar 27 2009, 104(6):805-812.
54. Andreadou I., Papaefthimiou M., Zira A., Constantinou M., Sigala F., Skaltsounis A.L., et al. Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein. NMR Biomed Jul 2009, 22(6):585-592.
55. Tan G., Lou Z., Liao W., Zhu Z., Dong X., Zhang W., et al. Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: a metabonomic method and its application. PLoS One 2011, 6(11):e27683.
56. Mervaala E., Biala A., Merasto S., Lempiainen J., Mattila I., Martonen E., et al. Metabolomics in angiotensin II-induced cardiac hypertrophy. Hypertension 2010 Feb, 55(2):508-515.
57. Alexander D., Lombardi R., Rodriguez G., Mitchell M.M., Marian A.J. Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy. Eur J Clin Invest May 2011, 41(5):527-538.
58. Kang S.M., Park J.C., Shin M.J., Lee H., Oh J., Ryu do H., et al. (1)H nuclear magnetic resonance based metabolic urinary profiling of patients with ischemic heart failure. Clin Biochem Mar 2011, 44(4):293-299.
59. Russell R.R., Taegtmeyer H. Pyruvate carboxylation prevents the decline in contractile function of rat hearts oxidizing acetoacetate. Am J Physiol Dec 1991, 261(6 Pt 2):H1756-H1762.
60. Russell R.R., Taegtmeyer H. Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate. J Clin Invest Feb 1991, 87(2):384-390.
61. Russell R.R., Mommessin J.I., Taegtmeyer H. Propionyl-L-carnitine-mediated improvement in contractile function of rat hearts oxidizing acetoacetate. Am J Physiol Jan 1995, 268(1 Pt 2):H441-H447.
62. Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev Jul 2005, 85(3):1093-1129.
63. Mayr M., Yusuf S., Weir G., Chung Y.L., Mayr U., Yin X., et al. Combined metabolomic and proteomic analysis of human atrial fibrillation. J Am Coll Cardiol Feb 5 2008, 51(5):585-594.
64. Wang T.J., Larson M.G., Vasan R.S., Cheng S., Rhee E.P., McCabe E., et al. Metabolite profiles and the risk of developing diabetes. Nat Med Apr 2011, 17(4):448-453.
65. Shah S.H., Bain J.R., Muehlbauer M.J., Stevens R.D., Crosslin D.R., Haynes C., et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet Apr 2010, 3(2):207-214.
66. Laferrere B., Reilly D., Arias S., Swerdlow N., Gorroochurn P., Bawa B., et al. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med Apr 27 2011, 3(80). [80re2].
67. Rhee E.P., Cheng S., Larson M.G., Walford G.A., Lewis G.D., McCabe E., et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest Apr 2011, 121(4):1402-1411.
68. Chiu H.C., Kovacs A., Ford D.A., Hsu F.F., Garcia R., Herrero P., et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest Apr 2001, 107(7):813-822.
69. Yagyu H., Chen G., Yokoyama M., Hirata K., Augustus A., Kako Y., et al. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest Feb 2003, 111(3):419-426.
70. Finck B.N., Lehman J.J., Leone T.C., Welch M.J., Bennett M.J., Kovacs A., et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest Jan 2002, 109(1):121-130.
71. Son N.H., Park T.S., Yamashita H., Yokoyama M., Huggins L.A., Okajima K., et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest 2007 Oct, 117(10):2791-2801.
72. Listenberger L.L., Ory D.S., Schaffer J.E. Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J Biol Chem May 4 2001, 276(18):14890-14895.
73. Borradaile N.M., Han X., Harp J.D., Gale S.E., Ory D.S., Schaffer J.E. Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J Lipid Res Dec 2006, 47(12):2726-2737.
74. Son N.H., Yu S., Tuinei J., Arai K., Hamai H., Homma S., et al. PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J Clin Invest Oct 2010, 120(10):3443-3454.
75. Sabatine M.S., Liu E., Morrow D.A., Heller E., McCarroll R., Wiegand R., et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation Dec 20 2005, 112(25):3868-3875.
76. Lewis G.D., Farrell L., Wood M.J., Martinovic M., Arany Z., Rowe G.C., et al. Metabolic signatures of exercise in human plasma. Sci Transl Med May 26 2010, 2(33). [33ra7].
77. Lewis G.D., Wei R., Liu E., Yang E., Shi X., Martinovic M., et al. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest Oct 2008, 118(10):3503-3512.
78. Obrzut S., Tiongson J., Jamshidi N., Phan H.M., Hoh C., Birgersdotter-Green U. Assessment of metabolic phenotypes in patients with non-ischemic dilated cardiomyopathy undergoing cardiac resynchronization therapy. J Cardiovasc Transl Res Dec 2010, 3(6):643-651.
79. McKnight S.L. On getting there from here. Science Dec 3 2010, 330(6009):1338-1339.
80. Li W., Bian F., Chaudhuri P., Mao X., Brunengraber H., Yu X. Delineation of substrate selection and anaplerosis in tricarboxylic acid cycle of the heart by 13C NMR spectroscopy and mass spectrometry. NMR Biomed Feb 2011, 24(2):176-187.
81. Jessen M.E., Kovarik T.E., Jeffrey F.M., Sherry A.D., Storey C.J., Chao R.Y., et al. Effects of amino acids on substrate selection, anaplerosis, and left ventricular function in the ischemic reperfused rat heart. J Clin Invest Aug 1993, 92(2):831-839.
82. Reed M.K., Barak C., Malloy C.R., Maniscalco S.P., Jessen M.E. Effects of glutamate and aspartate on myocardial substrate oxidation during potassium arrest. J Thorac Cardiovasc Surg Dec 1996, 112(6):1651-1660.
83. Malloy C.R., Jones J.G., Jeffrey F.M., Jessen M.E., Sherry A.D. Contribution of various substrates to total citric acid cycle flux and anaplerosis as determined by 13C isotopomer analysis and O2 consumption in the heart. MAGMA Mar 1996, 4(1):35-46.
84. Merritt M.E., Harrison C., Sherry A.D., Malloy C.R., Burgess S.C. Flux through hepatic pyruvate carboxylase and phosphoenolpyruvate carboxykinase detected by hyperpolarized 13C magnetic resonance. Proc Natl Acad Sci U S A Nov 22 2011, 108(47):19084-19089.
85. Merritt M.E., Harrison C., Storey C., Sherry A.D., Malloy C.R. Inhibition of carbohydrate oxidation during the first minute of reperfusion after brief ischemia: NMR detection of hyperpolarized 13CO2 and H13CO3. Magn Reson Med Nov 2008, 60(5):1029-1036.
86. Schroeder M.A., Atherton H.J., Dodd M.S., Lee P., Cochlin L.E., Radda G.K., et al. The cycling of acetyl-coenzyme A through acetylcarnitine buffers cardiac substrate supply: a hyperpolarized 13C magnetic resonance study. Circ Cardiovasc Imaging Mar 2012, 5(2):201-209.
87. Malloy C.R., Merritt M.E., Sherry A.D. Could 13C MRI assist clinical decision-making for patients with heart disease?. NMR Biomed Oct 2011, 24(8):973-979.